Not all patients with CLL need therapy. Regardless of all current advances, the iwCLL still endorses watchful observation for clients with asymptomatic ailment.86 This suggestion relies on at the very least two randomized trials comparing observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104 B